RxDoctor Payments Data

Duke Phan, MD

Neurology · Fountain Valley, CANPI 1437352630

Payments from drug & device makers

$2,799in general payments, 2019–2025

Across 29 payments — averaging $96.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$533
  • AstraZeneca$492
  • SK Life Science, Inc.$249
  • Amgen$242
  • AbbVie$206
  • Eisai Inc.$146
  • plus $931 from 10 others

What the payments were for

  • Food & beverage$2,797100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,799 in reported general payments places this provider in the 55th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$120,230
Medicare patients
274
Services billed
1,183

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4628$47,009
Nurtec OdtRimegepant Sulfate20$23,257
Entacapone84$19,742
Rasagiline Mesylate41$11,174
RytaryCarbidopa/Levodopa12$7,207
Pramipexole ErPramipexole Di-Hcl12$6,958
Lacosamide37$5,306
Carbidopa-LevodopaCarbidopa/Levodopa103$4,038
Levetiracetam104$3,579
Memantine Hcl168$3,237
Memantine Hcl ErMemantine Hcl20$3,028
Donepezil Hcl335$2,086
Pramipexole DihydrochloridePramipexole Di-Hcl112$1,651
Gabapentin110$1,241
Rivastigmine11$953

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$120$23,25720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,996 neurology providers in California.

Other neurology in Fountain Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →